Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are obviously letting massive convertible debt to crush the stock then do a shareholder crushing reverse. The problem is the convertibles just reset and start selling again. They will knock it back to sub penny in less than 1 month post reverse.
very typical of OTC and Pink companies.This used to work but no more
CEOs are delusional if they think this is a solution.
it looks like this will be knocked off of the OTCQB because it will close under .01 soon
just because they file for reverse will not stop that
it could be months or never for reverse to be approved
if it is not approved it will never be over .01 again
i was told that because of some of the peoples past deals that are running the show
reverse approval is unlikely
DILUTION ALERT: Another 6.8 mil shares getting freed up and should be in the market by next Tuesday
look out below
aggravating to say the least
once it goes under .01 expect a major reverse
that's what they all do
A bad day or 2 of convertibles dumping and this goes SUB PENNY
THEN THEY GET BOOTED OFF OF OTCQB
WHERE DID THE MOMENTUM GO? I AM GETTING KILLED ON THIS
Maybe mice are excited about RGBP news but the market sure isn't.
same old fluff news
no volume
falling stock price
whats the next big news? guinea pig results?
LMFAO
Koos dilution train taking RGBP to SUB PENNY !!!!!!
Convertibles look to be in control
and you know what they do .000 bid
05/15/2018 True North Energy Announces Updates to Recent Press Release Regarding Term Sheet Termination Press Release |
SPRING, TX / ACCESSWIRE / May 15, 2018 / True North Energy Corporation, a Nevada corporation (OTC PINK: TNEN) ("True North" or the "Company"), today provides further updates to the matters disclosed in its May 10, 2018 press release. Specifically, the Company announces that it has received a response to its letter from the owner of Kryptonite Korea Limited ("Kryptonite") wherein the Company proposed to rescind/cancel the Kryptonite acquisition and other commercial terms. Legal counsel for Kryptonite responded that Kryptonite was terminating the contract. Both parties reserve their rights for further action.
Additionally, the Company previously announced it had demanded payment on certain promissory note issued by migme ltd, an Australian company ("Migme") and its wholly-owned subsidiary, Amiki Pte Ltd. ("Amiki") to the Company. After further contemplation, the Company has decided not to proceed with that demand at this time.
About True North Energy Corporation
Traditionally, True North Energy Corporation has engaged in the identification, acquisition and development of oil and gas properties. Through its subsidiary, TN Energy Corp, a Texas Corporation, the Company holds overriding royalty interests on oil and gas properties located in Colorado and Oklahoma.
Contact
Synergy
Rick Severson
888.259.9173
rick@synergy-businessconsultants.com
This press release may contain forward-looking statements, including information about management's view of True North's future expectations, plans and prospects. In particular, when used in the preceding discussion, the words 'believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release, other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of True North, its divisions and concepts to be materially different than those expressed or implied in such statements. The forward-looking statements included in this press release are made only as of the date hereof. True North cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, True North undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by True North.
SOURCE: True North Energy Corporation
How can ENTB keep trading on offer at .035 and higher and there are never any bids?
something ain't right
Debt Resolve Reports Nine Month Rev of 2017 up 120%,
WHITE PLAINS, NY / ACCESSWIRE / November 13, 2017 / Debt Resolve, Inc. (OTC PINK: DRSV) today announced results for the quarter ending September 30, 2017. Revenue for this quarter was $955,819, as compared to $1,336,870 in the quarter ending September 30, 2016. Operating loss was ($189,762), as compared to an operating loss of ($8,416) in the quarter ending September 30, 2016. There was a Net Loss for the quarter ending September 30, 2017 of ($454,163) and a Net Loss Attributable to Debt Resolve, Inc. in the same quarter of ($381,261), as compared to a Net Loss of ($497,444) and a Net Loss Attributable to Debt Resolve, Inc. of ($558,605) in the quarter ending September 30, 2016. For the nine months ending September 30, 2017, the Company reported revenue of $5,161,735 in 2017, as compared to $2,342,344 in 2016. In the same period, operating income was $394,577 in 2017, as compared to an operating loss of ($943,141) in 2016.
"We are disappointed by Student Loan Care's sales employee turnover during the third quarter of 2017 and its resulting impact on our financial results," said Bruce Bellmare, Debt Resolve's CEO "While employee turnover is common in the call center industry, we were surprised by number of sales employees who elected to leave for short term gains rather than stay for the long term career opportunities at Student Loan Care."
Mr. Bellmare added, "New sales management and sales employees have been hired, trained and deployed to return Student Loan Care to the financial growth path demonstrated over the previous 4 quarters."
About Debt Resolve, Inc.
Debt Resolve's traditional SaaS business provides lenders, debt buyers, collection agencies, collection law firms and hospitals with a patent-protected online bidding system for the resolution and settlement of consumer debt. The company also provides web-based revenue management platforms for the healthcare industries that include cost-effective collection solutions for every stage of collection and recovery. Student Loan Care LLC is a Debt Resolve Inc. majority owned joint venture with Hutton Ventures and provides documentation preparation services for federal student loan modification and consolidation programs. The company is publicly held and trades on the OTC Markets under the symbol DRSV. Debt Resolve is headquartered in Hawthorne, New York.
Forward-Looking Statements
Certain statements in this press release and elsewhere by management of the Company that are neither reported financial results nor other historical information are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of the Company's operations varying significantly and materially from anticipated results. Debt Resolve undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by SEC rules. Investors are advised to consult any further disclosures made on related subjects in the Company's reports filed with the SEC.
Investor Relations:
Debt Resolve:
Wayne Travis
wtravis@debtresolve.com
If you own ELTZ and are concerned about the price, here is what you can do.
Be patient.
The funding acquired to make an excellent revenue producing company (Pirate)was necessary.
Almost all funding in pinksheets land is dilutive.
It is not unlimited.
There was value created.
There is no bad news out on ELTZ.
You can either buy on the dip.
Hold
Or Sell.
In any case, stop worrying on every single trade and every single day or you will get sick
This happens all of The time on OTCQB and Pinks.
Those who weather the storm and don't panic can really score.
IMO
DO YOUR OWN DUE DILIGENCE BEFORE MAKING ANY DECISIONS OR YOU ARE A FOOL.
Can someone sticky today's news?
ELTZ may be getting heavily shorted. I don't think is is all just dilution. Once the noteholder sells its shares they have to send in a conversion notice for more shares and it takes a little time. This has been non stop pounding. When you see the 3 Cs (CSTI CDEL and CANT) together on Level 2, it is a good indication they are shorting.
More news and some promotion will catch them and create a short squeeze.
ELTZ NEWS OUT !! Elite Group, Inc. announces acquisition of Pirate Oilfield Services, Inc.
FRISCO, TX -- (Marketwired) -- 11/01/17 -- Elite Group, Inc. (OTC PINK: ELTZ), a Nevada corporation established to acquire assets in the oil field service sector, is proud to announce it has acquired Pirate Oilfield Services, Inc. The company has executed a purchase and sale agreement for the company and closed the transaction September 12, 2017.
Pirate Oilfield Services, Inc. is an oil and gas service company located in Midland, Texas. Pirate provides multiple services to oil and gas companies including roustabout services, equipment rental, welding services, and many others. Pirate had revenue of $6.5 mil for 2016 and will do approximately $5 mil in revenue for 2017 due to the reorganization and ramp up. New services in addition to the roustabout work will be vacuum truck rental, grubber clearing and site, pipeline and pit construction. This new work will be added through Pirate's existing MSA's (Master Service Agreements) with multiple companies such as Pioneer, Energen, Anadarko, Koch Industries, Parsley, Sandridge, McGuire and others. Pirate estimates its revenue could increase to over $8 million for 2018.
Terry Tecco, CEO of ELTZ, commented, "Pirate Oilfield Services, Inc. is the initial acquisition for ELITE and will serve as the platform entity for future acquisitions. As part of our ongoing business strategy we will continue to research and identify additional acquisitions that fit our model."
The 8K for this transaction may be viewed in Elite Group, Inc.'s October 26, 2017 filing. https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12340348
About Elite Group, Inc. ELITE Group, Inc. is a Nevada corporation established to acquire assets in the oil field service sector. ELITE Group, Inc. specializes in the acquisition of assets related to the oil field services. Management's objective is to acquire and consolidate oil field service assets in the prolific oil and gas exploration areas - primarily in the Permian and Eagle Ford Basins. Management believes it will accomplish its goal to maximize shareholder value through strategic acquisitions, effective business model design and economies of scale to an expanding industry. Elite's management currently has relationships with a substantial number of oil and gas operators in the Permian and Eagle Ford basins. ELITE Group, Inc. will use the most environmentally friendly procedures and processes available to the industry.
About Pirate Oilfield Services Pirate Oilfield Services, Inc. is a company formed in 2013. The company was originally formed to provide oil and gas services and also began offering roustabout services to SandRidge Energy. Pirate expanded its services to include sandblasting and welding, although, roustabout services were the primary source of revenue through the summer of 2017. Pirate has 22 various trucks and had 13 three man roustabout crews running
Forward-Looking Statements
Certain statements in this press release and elsewhere by management of the Company that are neither reported financial results nor other historical information are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to actual results of the Company's operations varying significantly and materially from anticipated results. Elite Group, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by SEC rules. Investors are advised to consult any further disclosures made on related subjects in the Company's reports filed with the SEC.
Elite Group, Inc.
4760 Preston Road
#244-144
Frisco, TX 75034
http://www.elitegroupenergy.com
For Investor Relations:
Synergy: 1-888-259-9173
Source: Elite Group Inc.
https://www.otcmarkets.com/stock/ELTZ/news
RGBP GREAT NEWS OUT !!!!
Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6
Oct 03, 2017
OTC Disclosure & News Service
-
Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6
PR Newswire
SAN DIEGO, October 3, 2017
SAN DIEGO, October 3, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) scientists have used a standard biochemical assay to determine if some of its small molecules that have been shown to activate NR2F6 in cells, physically interact with NR2F6 in vitro. The Company reports that the experiments indicate that some of Regen's proprietary small molecules bind to, and alter the structure of NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have used a well-known biochemical assay, termed a thermal shift assay, to examine whether our drugs in development bind directly to NR2F6. We were delighted to see clear evidence of binding," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Although this specific assay does not tell us how tightly the drugs bind, it does tell us that binding is occurring. We are preparing another assay to answer the questions about affinity."
"It may sound pedestrian, but this is very important new information," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "It confirms all of our prior suppositions about mechanism, and gives us great confidence in our program moving forward."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharma.com
SOURCE Regen BioPharma, Inc.
RGBP looks like a small push on offer sends this to .09
not much on level to in .05 range
how about a little news ?
Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders
Dividend is Approximately 83% Payout of Zander's Issued and Outstanding Common Shares
SAN DIEGO, September 29, 2017 /PRNewswire/ --
Entest BioMedical, Inc. (OTC:ENTB) today announced that its Board of Directors has authorized a distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc. ("Dividend Shares"), a subsidiary of ENTB, to:
(a) Holders of record of the outstanding common shares of ENTB as of the record date
(b) Holders of record of the shares of any outstanding series of the preferred shares of ENTB as of the record date.
Entest BioMedical's Chairman & CEO, David Koos stated, "The record date is anticipated to be set as soon as possible after the Form S-1 registering the Dividend Shares under the Securities Act of 1933 is declared effective by the United States Securities and Exchange Commission (SEC). On a pro rata basis, both common and all classes of preferred shareholders will receive this dividend. The Company expects the registration statement to be filed within the next few days with the SEC."
About Zander Therapeutics Inc. and Entest BioMedical Inc.:
Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as an 'orphan nuclear receptor', which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (subsidiary of Entest BioMedical Inc.).
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Zander Therapeutics, Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.zandertherapeutics.com
info@zandertherapeutics.com
SOURCE Entest BioMedical Inc.
RGBP looks like a few 100K in buying sends this to .09
Level 2 thin.
I would not be surprised if we get some decent news soon.
Pet industry spending topped US$66 billion in 2016
http://www.petfoodindustry.com/articles/6370-pet-industry-spending-topped-us66-billion-in-2016
Overall spending in the pet industry has surpassed previous spending by more than US$6 billion, said Bob Vetere, president and CEO of the American Pet Products Association (APPA) at Global Pet Expo.
Pet industry spending for 2016 came in at a record high US$66.75 billion, up from US$60.28 billion in 2015, or a 10.7 percent growth. APPA’s annual comprehensive industry figures report covers pet spending in the market categories of: food, supplies/over-the-counter (OTC) medications, veterinary care, live animal purchases and other services.
Improved statistics on pet food spending
“While this shows a significant increase over last year, it is more reflective of an adjustment in data reporting than actual growth,” said Vetere in a press release. “Actual growth when compared to previous reporting methods is closer to 4 percent.”
“We do still expect growth in the category, although the growth percentage will level out again as we continue to access updated analytics from the same data report,” said Vetere.
The noticeable increase in pet food spending of 22.6 percent in 2016 is primarily due to APPA accounting for new data from the US Bureau of Labor Statistics (US BLS), which indicated previous spending figures released may have been too conservative. With US$28.23 billion spent, the increase in this category now accurately reflects the steady growth the pet food industry has experienced all along. Interest in high end, premium pet food and treats continues to be a key driver for increased spending in the pet food category.
“Now that millennials have officially taken the reins as primary demographic of pet owners, they stand to further develop the humanization of pets trend,” said Vetere. “We’ve been anxious to see how this new group of pet owners will affect the industry, and now that they’re here and the industry spending is higher than ever, it’s a promising sign that our country’s pets are in good hands.”
Veterinary care spending remains the second source of spending in the pet industry at US$15.95 billion. While routine veterinary visits have not necessarily increased, new advances in health care and services available may be contributing to the 3.4 percent growth. Additionally, there is growing research on the human health benefits of pets and research from the Human Animal Bond Research Institute shows that the more pet owners become aware of the health benefits of their pets, the more likely they are to take care of them.
The third highest source of spending is in supplies and over the counter (OTC) medications. Up 3.0 percent from 2015, US$14.71 billion was spent on items such as beds, collars, leashes, toys, travel items, clothing, food and water bowls, and other accessories. Live animal purchases continue to decrease for the third year in a row, down .9 percent to US$2.1 billion in 2016.
Other services such as grooming, boarding, walking, training, pet sitting, yard services and more saw significant growth from 2015, second only to pet food category growth. While spending on pet services is behind the next closest spending segment by nearly US$9 billion, category growth for the past few years is something to take note of. It is even estimated to grow another six percent in 2017, higher than expected growth percentage for any other spending segment.
RGBP .05 to .10 could happen quickly.
Technically speaking Level 2 is very thin to .09
little news could go a long way.
As the end of Regen's fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.
The Marketplace:
Our decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning. Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (http://www.prnewswire.com/news-releases/regen-biopharma-inc-addresses-potential-impact-of-recent-bristol-myers-squibb-23-billion-acquisition-of-ifm-therapeutics-639392183.html), and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion).
A Look Back at our Success:
The scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity. Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.
Plans for the Immediate Future:
We continue to have discussions with multiple big pharma companies. To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, the greater their valuation in the marketplace.
We are now in the process of identifying the major indications on which we will focus our efficacy studies. Obviously, the market size of an indication is important, but equally or even more important is the likelihood of success. Therefore, although we already have a preferred list of indications, we will test these compounds for efficacy in many models of autoimmunity and cancer. Our goal in 2018 is to develop both an activator and inhibitor of NR2F6 that is effective and not toxic in animal models. At that point, we will begin experiments and process manufacturing, which will enable us to apply for testing these compounds in humans.
The drug development process is slow and steady. However, we have had no scientific setbacks, and the small molecule drugs that we are developing are performing exactly as we had hoped they would. This is not usually the case in science and we remain laser-focused on achieving the scientific goals we have set out to achieve. Thus far, we have met each and every scientific target, and we believe that our planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies in the near future.
With warm regards,
Harry Lander
President and Chief Scientific Officer
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
RGBP could very easily be bought out.
Huge upside.
Major consolidation, acquisitions and mergers in this industry by huge corporations.
Don;t think it would be sold for less than .10 per share.
The farther along the research goes the higher the selling price .
RGBP has been hanging tough around .04
Looks like Level 2 is pretty thin up to .09
I think a little news could go a long way putting a charge in PPS
RGBP looks like it will BREAK OUT soon.
too many good things going on for this to be under .07
ALL POSTS ARE MY OPINION ONLY. DO YOUR OWN DUE DILIGENCE !!!!!